by MM360 Staff | Sep 26, 2025 | Publications
Ann Med. 2025 Dec;57(1):2560679. doi: 10.1080/07853890.2025.2560679. Epub 2025 Sep 24. ABSTRACT OBJECTIVE: Smoldering multiple myeloma (SMM) is a slowly progressive, asymptomatic plasma cell disorder. This meta-analysis evaluated the efficacy and safety of novel...
by MM360 Staff | Sep 14, 2025 | Publications
Cancers (Basel). 2025 Aug 22;17(17):2727. doi: 10.3390/cancers17172727. ABSTRACT Background: Multiple myeloma (MM) is an incurable plasma cell dyscrasia with particularly adverse prognosis in relapsed, multi-drug refractory settings. The management of those patients...
by MM360 Staff | Sep 3, 2025 | Publications
ESMO Open. 2025 Aug;10(8):105514. doi: 10.1016/j.esmoop.2025.105514. Epub 2025 Jul 15. ABSTRACT BACKGROUND: The treatment landscape for relapsed/refractory multiple myeloma (RRMM) is rapidly evolving, particularly for patients exposed or refractory to lenalidomide....
by MM360 Staff | Aug 19, 2025 | Publications
Haematologica. 2025 Aug 14. doi: 10.3324/haematol.2025.288174. Online ahead of print. ABSTRACT Not available. PMID:40820831 | DOI:10.3324/haematol.2025.288174
by MM360 Staff | Aug 10, 2025 | Publications
BMC Cancer. 2025 Aug 8;25(1):1288. doi: 10.1186/s12885-025-14724-6. ABSTRACT BACKGROUND: There is a need to better reflect the patient experience in multiple myeloma (MM), beyond just clinical progression, with the use of a novel endpoint that combines disease...
by MM360 Staff | Jul 25, 2025 | Publications
Rofo. 2025 Jul 23. doi: 10.1055/a-2625-5643. Online ahead of print. ABSTRACT Multiple myeloma (MM) is the second most common hemato-oncological malignancy, characterized by the clonal proliferation of malignant plasma cells and bone marrow infiltration. The degree of...
